Apr 03, 2023 / 02:10PM GMT
Debjit Chattopadhyay - Guggenheim - MD, Biotechnology
Good morning, and thank you for joining the fifth annual Guggenheim Genomic Medicines and Rare Disease Conference. I am Debjit and my pleasure to have John Evans, the Chief Executive Officer of Beam Therapeutics.
John Evans - Beam Therapeutics Inc. - CEO & Board Member
Great to be here.
Questions and Answers:
Debjit Chattopadhyay - Guggenheim - MD, BiotechnologyAwesome, so let's maybe help people understand base editing and more because I think a lot of people don't understand what Beam stands for.
John Evans - Beam Therapeutics Inc. - CEO & Board Member
That's right. Yeah, it's actually a joke we tell that Beam stands for base editing and more, and we're always looking for what the And more is. And I think we've figured a lot of things out actually that fit into that bucket.
So Beam is a next-generation gene editing company. We work on CRISPR, but it's a new form of CRISPR. So we're using CRISPR
Trustpilot
